As the main implementing partner of TREAT TB, Vital Strategies oversees implementation of all TREAT TB activities. Vital Strategies is the sponsor of the STREAM clinical trial, directly manages all investigational medicinal products, and coordinates all other aspects of the trial in partnership with The International Union against Tuberculosis and Lung Disease, the Medical Research Council at University College London, the Liverpool School of Tropical Medicine, the Institute of Tropical Medicine, and REDE-TB. Vital Strategies’ operational research training and technical assistance activities are conducted in partnership with The International Union Against Tuberculosis and Lung Disease.
Vital Strategies is a non-profit organization focused on rapidly designing and implementing public health initiatives that bridge the gap between public health needs and solutions, especially in low- and middle-income countries. Vital Strategies values speed, attention to detail, evidence-based decision-making, and an appreciation of the scale needed to solve health problems.
Institute of Tropical Medicine Antwerp
The Institute of Tropical Medicine (ITM) in Antwerp, Belgium is the central microbiology laboratory for the STREAM clinical trial. It also provides technical assistance and training to laboratory scientists at STREAM sites.
ITM is one of the world’s leading institutes for training, research and service delivery in tropical medicine and health care in developing countries.
Liverpool School of Tropical Medicine
The Liverpool School of Tropical Medicine (LSTM) in Liverpool, England is the chief investigator for the health economics component of the STREAM Trial.
LSTM is an international postgraduate center of excellence, devoted to research, education, and consultancy, whose mission is to promote improved health, particularly in less developed countries in the tropics and sub-tropics.
London School of Hygiene and Tropical Medicine
Through the TREAT TB project, the London School of Hygiene and Tropical Medicine, in collaboration with Avenir Health, developed the TIME model. TIME is used by national tuberculosis programs in low- and middle-income countries to improve TB care and prevention by strengthening policies and enabling local capacity building. The objectives of TIME are to inform TB policy decision-making at the national and sub-national level by applying a comprehensive and accessible modeling framework and enable local capacity building and ownership through training and support.
The mission of the London School of Hygiene and Tropical Medicine is to improve health and health equity in the UK and worldwide; working in partnership to achieve excellence in public and global health research, education and translation of knowledge into policy and practice.
Medical Research Council at University College London
The Medical Research Council at University College London (MRC) is the coordinator for the STREAM trial and is responsible for implementation and oversight of all aspects of the trial. The co-Chief Investigators for the trial are affiliated with MRC.
The MRC’s mission is to improve human health through world-class medical research. To achieve this, MRC supports research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas.
The Brazilian Network of Tuberculosis Research (REDE-TB) in Rio de Janeiro, Brazil is the international coordinator for all STREAM community engagement activities.
REDE-TB aims to build scientific and technological capacity for the development of new technologies and new products, as well as collaboration in the review of public policies necessary for the control of tuberculosis. It also aims to capacitate professionals through postgraduate courses and training.
The International Union Against Tuberculosis and Lung Disease
The International Union Against Tuberculosis and Lung Disease (The Union) was the initial implementer of TREAT TB and continues to be Vital Strategies’ principal technical partner for all TREAT TB activities.
The Union draws from the best scientific evidence and expertise to advance solutions to public health challenges affecting people living in poverty. The Union promotes national autonomy within the framework of the priorities of each country by developing, implementing and assessing anti-tuberculosis, lung health and non-communicable disease program, as well as other public health issues.
As part of the TREAT TB project, the Yale University School of Public Health is conducting a three-year prospective observational study in Moldova, a high MDR-TB burden country, to evaluate universal whole genome sequencing of Mycobacterium tuberculosis to inform public health decisions. The study brings together pathogen genomic, spatial, epidemiological, demographic, and laboratory information in an effort to characterize existing TB transmission patterns, estimate the impact of TB interventions, and better understand the relative contribution of acquired and transmitted resistance to the MDR-TB epidemic in Moldova.
Through its innovative research, policy analysis, and education that draws upon multidisciplinary scholarship, Yale University’s School of Public Health aims to provide leadership to protect and improve the health of the public.
Since 2008, the United States Agency for International Development (USAID) has funded the TREAT TB project under a cooperative agreement with The Union, and now Vital Strategies.
USAID’s mission is to lead the U.S. Government’s international development and disaster assistance through partnerships and investments that save lives, reduce poverty, strengthen democratic governance, and help people emerge from humanitarian crises and progress beyond assistance.
Janssen Research & Development LLC is a co-funder for Stage 2 of the STREAM clinical trial and provides bedaquiline for the trial.
Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen is headquartered in Beerse, Belgium and aspires to transform lives by bringing life-saving and life-changing solutions to people who need them.